Amicus Therapeutics, Inc. (NASDAQ:FOLD – Get Rating) Director Margaret G. Mcglynn sold 15,000 shares of the business’s stock in a transaction dated Monday, May 2nd. The shares were sold at an average price of $6.99, for a total transaction of $104,850.00. Following the completion of the sale, the director now directly owns 38,034 shares of the company’s stock, valued at $265,857.66. The transaction was disclosed in a legal filing with the SEC, which is available through the SEC website.
NASDAQ FOLD opened at $7.17 on Thursday. The company has a current ratio of 4.09, a quick ratio of 3.90 and a debt-to-equity ratio of 1.27. The company has a 50 day moving average price of $8.62 and a 200 day moving average price of $9.86. Amicus Therapeutics, Inc. has a 52 week low of $6.66 and a 52 week high of $12.63.
Amicus Therapeutics (NASDAQ:FOLD – Get Rating) last posted its quarterly earnings data on Thursday, February 24th. The biopharmaceutical company reported ($0.29) EPS for the quarter, missing the consensus estimate of ($0.14) by ($0.15). The firm had revenue of $82.15 million for the quarter, compared to the consensus estimate of $82.57 million. Amicus Therapeutics had a negative return on equity of 87.21% and a negative net margin of 81.98%. During the same quarter last year, the firm earned ($0.27) EPS. As a group, equities analysts forecast that Amicus Therapeutics, Inc. will post -0.83 EPS for the current year.
Several equities research analysts have issued reports on FOLD shares. The Goldman Sachs Group initiated coverage on shares of Amicus Therapeutics in a research report on Wednesday, April 13th. They issued a “neutral” rating for the company. Cantor Fitzgerald reduced their price target on shares of Amicus Therapeutics from $16.00 to $15.00 and set an “overweight” rating for the company in a report on Thursday, January 13th. StockNews.com initiated coverage on shares of Amicus Therapeutics in a report on Thursday, March 31st. They issued a “hold” rating for the company. Finally, SVB Leerink reduced their price target on shares of Amicus Therapeutics from $16.00 to $14.00 and set an “outperform” rating for the company in a report on Thursday, February 24th. Five investment analysts have rated the stock with a hold rating and six have issued a buy rating to the company’s stock. According to data from MarketBeat, Amicus Therapeutics has an average rating of “Buy” and an average target price of $15.14.
Amicus Therapeutics Company Profile (Get Rating)
Amicus Therapeutics, Inc, a biotechnology company, focuses on discovering, developing, and delivering medicines for rare diseases. Its commercial product and product candidates include Galafold, an oral precision medicine for the treatment of adults with a confirmed diagnosis of Fabry disease and an amenable galactosidase alpha gene variant based on in vitro assay data.
- Get a free copy of the StockNews.com research report on Amicus Therapeutics (FOLD)
- World Wresting Entertainment Stock is Hulking Up
- High-Yield Weyco Group Returns To Reasonable Levels
- MarketBeat Podcast: Alternative Investing Strategies Despite Market Volatility
- Limelight Networks Stock is a Speculative Turnaround Opportunity
- The Selloff In SiteOne Landscape Supply Is Overextended
Receive News & Ratings for Amicus Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Amicus Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.